CAPR vs. BHVN, FOLD, MTSR, LGND, SDGR, MIRM, GMTX, NAMS, BLTE, and BHC
Should you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Biohaven (BHVN), Amicus Therapeutics (FOLD), Metsera (MTSR), Ligand Pharmaceuticals (LGND), Schrödinger (SDGR), Mirum Pharmaceuticals (MIRM), Gemini Therapeutics (GMTX), NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical preparations" industry.
Capricor Therapeutics vs.
Capricor Therapeutics (NASDAQ:CAPR) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings.
In the previous week, Biohaven had 16 more articles in the media than Capricor Therapeutics. MarketBeat recorded 20 mentions for Biohaven and 4 mentions for Capricor Therapeutics. Capricor Therapeutics' average media sentiment score of 1.10 beat Biohaven's score of 0.77 indicating that Capricor Therapeutics is being referred to more favorably in the media.
Capricor Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500.
Capricor Therapeutics currently has a consensus target price of $34.50, suggesting a potential upside of 190.89%. Biohaven has a consensus target price of $62.54, suggesting a potential upside of 174.77%. Given Capricor Therapeutics' higher probable upside, equities research analysts plainly believe Capricor Therapeutics is more favorable than Biohaven.
Biohaven received 47 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. Likewise, 67.44% of users gave Biohaven an outperform vote while only 63.78% of users gave Capricor Therapeutics an outperform vote.
Capricor Therapeutics has higher revenue and earnings than Biohaven. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Biohaven has a net margin of 0.00% compared to Capricor Therapeutics' net margin of -146.86%. Capricor Therapeutics' return on equity of -112.95% beat Biohaven's return on equity.
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by insiders. Comparatively, 16.0% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Biohaven beats Capricor Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Capricor Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Capricor Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CAPR) was last updated on 5/3/2025 by MarketBeat.com Staff
Buy CAPR Stock Free CAPR Stock Alerts